Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine

Growth Factor ◽

Pancreas Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Human Pancreas ◽

Vascular Endothelial ◽

Therapeutic Approaches ◽

Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation

The Oncologist ◽

10.1002/onco.13897 ◽

2021 ◽

Author(s):

Akhilesh Sivakumar ◽

Sarah E. Caulfield ◽

Chao Zhang ◽

Subir Goyal ◽

Mehmet A. Bilen ◽

...

Keyword(s):

Retrospective Study ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Bleeding Risk ◽

Vascular Endothelial ◽

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)80145-9 ◽

2004 ◽

Vol 2 (8) ◽

pp. 44 ◽

Cited By ~ 6

Author(s):

A. Tolcher ◽

J.J. O'Leary ◽

J. DeBono ◽

K. Molpus ◽

C. Woodard ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Phase I Study ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Everolimus zur Behandlung des metastasierten Nierenzellkarzinoms nach Versagen der ersten VEGFr-TKI(Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor)-Therapie: Ergebnisse einer Interimsanalyse einer nichtinterventionellen Studie

Karger Kompass Onkologie ◽

10.1159/000356898 ◽

2014 ◽

Vol 1 (1) ◽

pp. 28-29

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Receptor Tyrosine Kinase Inhibitor ◽

Everolimus in Patients with Metastatic Renal Cell Carcinoma Who Progress after Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFR-TKI) Therapy: UK Results from the react Trial on Behalf of the UK React Investigators

Annals of Oncology ◽

10.1016/s0923-7534(20)33390-1 ◽

2012 ◽

Vol 23 ◽

pp. ix271-ix272

Author(s):

S. Chowdhury ◽

J. Larkin

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Renal Cell ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

The Uk ◽

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research ◽

10.1158/0008-5472.can-07-5809 ◽

2008 ◽

Vol 68 (12) ◽

pp. 4754-4762 ◽

Cited By ~ 86

Author(s):

Caroline A. Heckman ◽

Tanja Holopainen ◽

Maria Wirzenius ◽

Salla Keskitalo ◽

Michael Jeltsch ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Abstract 3681: Vascular endothelial growth factor receptor tyrosine kinase inhibitor inhibited mutated epidermal growth factor receptor-driven tumors ex vivo and in vivo

10.1158/1538-7445.am2011-3681 ◽

2011 ◽

Author(s):

Toshio Kubo ◽

Kadoaki Ohashi ◽

Masahiro Osawa ◽

Hiromasa Takeda ◽

Eiki Ichihara ◽

...

Keyword(s):

Growth Factor ◽

Kinase Inhibitor ◽

Ex Vivo ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Epidermal Growth ◽

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study

European Journal of Cancer ◽

10.1016/j.ejca.2011.11.027 ◽

2012 ◽

Vol 48 (3) ◽

pp. 333-339 ◽

Cited By ~ 86

Author(s):

E. Calvo ◽

B. Escudier ◽

R.J. Motzer ◽

S. Oudard ◽

T.E. Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Subgroup Analysis ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Phase Iii ◽

Vascular Endothelial ◽

Editorial Comment to Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor

International Journal of Urology ◽

10.1111/iju.12423 ◽

2014 ◽

Vol 21 (7) ◽

pp. 741-741

Author(s):

Yoshihiro Wada

Keyword(s):

Renal Cell Carcinoma ◽

Growth Factor ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Previously Treated ◽

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo

NMR in Biomedicine ◽

10.1002/nbm.961 ◽

2005 ◽

Vol 18 (5) ◽

pp. 308-321 ◽

Cited By ~ 44

Author(s):

Markus Rudin ◽

Paul M. J. McSheehy ◽

Peter R. Allegrini ◽

Martin Rausch ◽

Diana Baumann ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Contrast Agent ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro

PLoS ONE ◽

10.1371/journal.pone.0124234 ◽

2015 ◽

Vol 10 (4) ◽

pp. e0124234 ◽

Cited By ~ 5

Author(s):

Attila Varga ◽

Pál Gyulavári ◽

Zoltán Greff ◽

Krisztina Futosi ◽

Tamás Németh ◽

...

Keyword(s):

Growth Factor ◽

Protein Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Protein Kinase D1 ◽

Endothelial Growth Factor ◽

Multiple Kinase Inhibitor